Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Par_Pharmaceutical
Indevus Pharmaceuticals Paladin Labs Qualitest Pharmaceuticals |
| gptkbp:CEO |
Blaise Coleman
|
| gptkbp:countryOfOrigin |
gptkb:United_States
|
| gptkbp:filedForBankruptcy |
2022
|
| gptkbp:founded |
1997
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Endo Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:legalIssue |
opioid litigation
|
| gptkbp:market |
oncology
endocrinology pain management urology branded pharmaceuticals specialty pharmaceuticals generic pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Percocet
gptkb:Opana Xiaflex Supprelin LA Vasostrict |
| gptkbp:numberOfEmployees |
~3,000
|
| gptkbp:parentCompany |
Endo International plc
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ENDP
|
| gptkbp:website |
https://www.endo.com/
|
| gptkbp:bfsParent |
gptkb:Percocet
gptkb:David_Holveck |
| gptkbp:bfsLayer |
7
|